Kaichuan Zhu

Kaichuan Zhu

Auto-generated profile, based on publicly available information

Kaichuan Zhu

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
XXXianyuan Xiang
Xianyuan Xiang
TPThomas Piers
Thomas Piers
BWBenedikt Wefers
Benedikt Wefers
KZKaichuan Zhu
Kaichuan Zhu
AMAnna Mallach
Anna Mallach
CHChristian Haass
Christian Haass
The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease. A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor. Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant. The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.

1 March 2018 in Biological Psychiatry
Verified
Journal Article
Open access
KZKaichuan Zhu
Kaichuan Zhu
XXXianyuan Xiang
Xianyuan Xiang
SFSeverin Filser
Severin Filser
PMPetar Marinković
Petar Marinković
MDMario M. Dorostkar
Mario M. Dorostkar
JHJochen Herms
Jochen Herms
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a promising drug target for the treatment of Alzheimer's disease. Prolonged BACE1 inhibition interferes with structural and functional synaptic plasticity in mice, most likely by altering the metabolism of BACE1 substrates. Seizure protein 6 (SEZ6) is predominantly cleaved by BACE1, and Sez6 knockout mice share some phenotypes with BACE1 inhibitor-treated mice. We investigated whether SEZ6 is involved in BACE1 inhibition-induced structural and functional synaptic alterations. The function of NB-360, a novel blood-brain barrier penetrant and orally available BACE1 inhibitor, was verified by immunoblotting. In vivo microscopy was applied to monitor the impact of long-term pharmacological BACE1 inhibition on dendritic spines in the cerebral cortex of constitutive and conditional Sez6 knockout mice. Finally, synaptic functions were characterized using electrophysiological field recordings in hippocampal slices. BACE1 enzymatic activity was strongly suppressed by NB-360. Prolonged NB-360 treatment caused a reversible spine density reduction in wild-type mice, but it did not affect Sez6-/- mice. Knocking out Sez6 in a small subset of mature neurons also prevented the structural postsynaptic changes induced by BACE1 inhibition. Hippocampal long-term potentiation was decreased in both chronic BACE1 inhibitor-treated wild-type mice and vehicle-treated Sez6-/- mice. However, chronic NB-360 treatment did not alter long-term potentiation in CA1 neurons of Sez6-/- mice. Our results suggest that SEZ6 plays an important role in maintaining normal dendritic spine dynamics. Furthermore, SEZ6 is involved in BACE1 inhibition-induced structural and functional synaptic alterations.

29 August 2016 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CZChengyu Zou
Chengyu Zou
SCSophie Crux
Sophie Crux
Stéphane MarinescoStéphane Marinesco
Stéphane Marinesco
EMElena Montagna
Elena Montagna
CSCarmelo Sgobio
Carmelo Sgobio
JHJochen Herms
Jochen Herms
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 October 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
KZKaichuan Zhu
Kaichuan Zhu
FPFinn Peters
Finn Peters
SFSeverin Filser
Severin Filser
JHJochen Herms
Jochen Herms

1 February 2019 in Behavioural Brain Research
Verified
Journal Article
Closed access
SSSebastian Schmid
Sebastian Schmid
GRGerhard Rammes
Gerhard Rammes
MBManfred Blobner
Manfred Blobner
KKKristine Kellermann
Kristine Kellermann
SBSebastian Bratke
Sebastian Bratke
BJBettina Jungwirth
Bettina Jungwirth

28 August 2023 in Glia
Verified
Journal Article
Open access
XCXuezhen Chen
Xuezhen Chen
YZYue Zhao
Yue Zhao
YHYimin Huang
Yimin Huang
KZKaichuan Zhu
Kaichuan Zhu
FZFan Zeng
Fan Zeng
XXXianyuan Xiang
Xianyuan Xiang
Triggering receptor expressed on myeloid cell 2 (TREM2), a myeloid cell‐specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor‐associated macrophages in different types of cancer. Here, we studied whether TREM2 influences glioma progression. We found a gender‐dependent effect of glioma growth in wild‐type (WT) animals injected with GL261‐EGFP glioma cells. Most importantly, TREM2 promotes glioma progression in male but not female animals. The accumulation of glioma‐associated microglia/macrophages (GAMs) and CD31+ blood vessel density is reduced in male TREM2‐deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses immune‐related genes. In an organotypic slice model devoid of functional vascularization and immune components from periphery, the tumor size was not affected by TREM2‐deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the Cancer Genome Atlas Program (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases, the TREM2 expression levels were negatively correlated with survival. Thus, the TREM2‐dependent crosstalk between GAMs and the vasculature formation promotes glioma growth.